Symbiq was the first general infusion system to provide additional medication-error protection, with the EndoTool being a sophisticated glucose management system designed to develop the safety and quality of care.
Philip Settimi, VP, Global Marketing, Global Devices, Hospira, said: “Unveiling the integrated Symbiq and EndoTool development effort illustrates Hospira’s commitment to providing cutting-edge medication delivery technology, and ensuring compatibility between and integration of important hospital technologies.”
The company is targeting a 510(k) submission to the US Food and Drug Administration (FDA) for the integrated Symbiq/EndoTool system by the end of the year.
